Facklamia: Difference between revisions
From IDWiki
Facklamia
m (Text replacement - " species}}" to "") |
mNo edit summary |
||
| Line 25: | Line 25: | ||
* Antimicrobial Susceptibilities and Clinical Sources of ''Facklamia'' Species. ''Antimicrob Agents Chemother''. 2000;44(8):2130-2132. doi: [https://doi.org/10.1128/aac.44.8.2130-2132.2000 10.1128/aac.44.8.2130-2132.2000] |
* Antimicrobial Susceptibilities and Clinical Sources of ''Facklamia'' Species. ''Antimicrob Agents Chemother''. 2000;44(8):2130-2132. doi: [https://doi.org/10.1128/aac.44.8.2130-2132.2000 10.1128/aac.44.8.2130-2132.2000] |
||
| + | |||
| − | {{DISPLAYTITLE:''Facklamia'' |
+ | {{DISPLAYTITLE:''Facklamia''}} |
[[Category:Gram-positive cocci]] |
[[Category:Gram-positive cocci]] |
||
Revision as of 13:01, 25 January 2022
Background
Microbiology
- Genus of Gram-positive cocci in chains or diplococci (or for F. languida, in clusters)
- Previously would have been identified as a viridans group streptococcus
- Includes five species:
- Facklamia hominis
- Facklamia ignava
- Facklamia languida
- Facklamia sourekii
- Faklamia tabacinasalis
Clinical Presentation
- Rare opportunistic pathogen primarily presenting with bacteremia
- Case reports of vaginitis, wound infection, abscess, meningitis, and osteomyelitis
Management
- Similar to viridans groups streptococci
- Often susceptible to penicillins and cephalosporins, but not always (20 to 50% resistance)
Further Reading
- Antimicrobial Susceptibilities and Clinical Sources of Facklamia Species. Antimicrob Agents Chemother. 2000;44(8):2130-2132. doi: 10.1128/aac.44.8.2130-2132.2000
